BIOSYNEX Diagnostics

BIOSYNEX Diagnostics is a major European player in the in-vitro diagnostic market, offering rapid membrane tests. Founded in 2005, the company has built a strong reputation for innovation and high-quality customer service. With a keen focus on customer needs and leveraging their cutting-edge Research and Development labs in France, BIOSYNEX continuously develops and introduces ground-breaking products. The company's dedication to providing innovative diagnostic tests aligns with their goal of supporting healthcare professionals in making critical, life-saving decisions.

Operating in the Biotechnology, Manufacturing, and Marketing sectors, BIOSYNEX has captured the attention of investors, evident in the Post-IPO Equity investment on 26 November 2021. This financial milestone underscores the market's confidence in BIOSYNEX's potential for growth and impact within the diagnostic industry.

As one of the leading forces in the European in-vitro diagnostic market, BIOSYNEX's commitment to innovation and customer-centric approach positions the company as a noteworthy investment prospect, poised for sustained success and positive contributions to the medical field.